Norbinaltorfimin

Из Википедије, слободне енциклопедије
Norbinaltorfimin
Nor-BNI.png
IUPAC ime
17,17'-(dicyclopropylmethyl)-6,6',7,7'-6,6'-imino- 7,7'-binorphinan-3,4',14,14'-tetrol
Identifikatori
CAS broj 105618-26-6 ДаY
ATC kod none
PubChem CID 3034416
IUPHAR/BPS 1642
Hemijski podaci
Formula C40H43N3O6
Molarna masa 661.784 g/mol
  (verify)

Norbinaltorphimin (nor-BNI) je opioidni antagonist koji se koristi u naučnim istraživanjima. On je jedan od malobrojnih dostupnih opioidnih antagonista koji su visoko selektivni za κ-opioidni receptor, i blokiraju taj receptor bez uticaja na μ- ili δ-opioidni receptor.[1] although On je manje selektivan in vivo nego kad se koristi u izolovanim tkivima.[2] nor-BNI blokira efekte kapa agonista u životinjskim modelima,[3][4] i proizvodi antidepresantske efekte.[5]

Vidi još[уреди]

Literatura[уреди]

  1. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sciences. 1987 Mar 30;40(13):1287-92. PMID 2882399
  2. Birch PJ, Hayes AG, Sheehan MJ, Tyers MB. Norbinaltorphimine: antagonist profile at kappa opioid receptors. European Journal of Pharmacology. 1987 Dec 15;144(3):405-8. PMID 2831070
  3. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. Journal of Pharmacology and Experimental Therapeutics. 1988 Jul;246(1):255-8. PMID 2839664
  4. Takemori AE, Schwartz MM, Portoghese PS. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. Journal of Pharmacology and Experimental Therapeutics. 1988 Dec;247(3):971-4. PMID 2849679
  5. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. Journal of Neurochemistry. 2004 Sep;90(5):1258-68. DOI 10.1111/j.1471-4159.2004.02589.x} PMID 15312181

Spoljašnje veze[уреди]

Star of life.svg     Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).